4D Molecular Therapeutics (FDMT) Operating Income (2020 - 2026)

4D Molecular Therapeutics (FDMT) has 7 years of Operating Income data on file, last reported at -$73.6 million in Q1 2026.

• Operating Income for Q1 2026 came in at -$73.6 million, down 37.3% year-over-year; the trailing twelve-month figure through Mar 2026 was -$179.5 million (up 11.7% YoY), and the FY2025 annual result was -$159.5 million, up 15.06% from the prior year.
• Operating Income retreated to -$73.6 million in Q1 2026 per FDMT's latest filing, from $14.7 million in the prior quarter.
• Over five years, Operating Income peaked at $14.7 million in Q4 2025 and troughed at -$73.6 million in Q1 2026.
• A 5-year average of -$37.9 million and a median of -$36.7 million in 2023 frame the typical range for Operating Income.
• The sharpest annual moves came in 2022 and 2025: Operating Income sank 274.22% in 2022, then surged 126.22% in 2025.
• A 5-year view of Operating Income shows it stood at -$28.7 million in 2022, then dropped by 27.62% to -$36.7 million in 2023, then slumped by 53.11% to -$56.1 million in 2024, then surged by 126.22% to $14.7 million in 2025, then tumbled by 600.31% to -$73.6 million in 2026.
• Business Quant data shows FDMT's Operating Income at -$73.6 million in Q1 2026, $14.7 million in Q4 2025, and -$61.2 million in Q3 2025.